|
|
||||||||
From the Glaucoma Center, University of California San Diego, La Jolla.
PURPOSE. To determine whether exposure of sclera to latanoprost acid alters transscleral permeation by FGF-2.
METHODS. Pieces of human sclera were isolated from donor eyes after death, placed in organ culture, and exposed to 50 to 200 nM latanoprost acid or vehicle for 3 days. Transscleral permeability was then assessed by placing each scleral piece into a Ussing apparatus and measuring the amount of FGF-2 that moves from the orbital side to the uveal side of the scleral piece. Transscleral permeation by 10-kDa tetramethylrhodamine-dextran also was determined, for comparison.
RESULTS. Transscleral permeation by FGF-2 through sclera that had been incubated with vehicle was 1.53 ± 0.86 x 10-8 cm/sec. Transscleral permeation by 10-kDa tetramethylrhodamine-dextran was 1.04 ± 0.39 x 10-6 cm/sec. FGF-2 permeation of sclera exposed to 50, 100, and 200 nM latanoprost acid was increased by an average of 48% ± 62%, 100% ± 108%, and 108% ± 79%, respectively, compared with sclera exposed to vehicle (n = 13; P < 0.05). Scleral permeation by 10-kDa dextran after exposure to 50, 100, or 200 nM latanoprost acid was significantly increased by 42% ± 36%, 59% ± 51%, and 65% ± 49%, respectively (n = 14; P < 0.05). The ratio of dextran to FGF-2 permeation was approximately 90 and did not vary with 50, 100, or 200 nM latanoprost acid (P = 0.93, ANOVA).
CONCLUSIONS. Exposure of sclera to latanoprost acid increases transscleral permeation by FGF-2 in human scleral organ cultures. Because this increase parallels the increased scleral permeability caused by dextran, it may reflect a general enhancement of permeability, a possibility that future in vivo studies should explore.
This article has been cited by other articles:
![]() |
M. Seki, W. Soussou, S.-i. Manabe, and S. A. Lipton Protection of Retinal Ganglion Cells by Caspase Substrate-Binding Peptide IQACRG from N-Methyl-D-Aspartate Receptor-Mediated Excitotoxicity Invest. Ophthalmol. Vis. Sci., February 1, 2010; 51(2): 1198 - 1207. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Okabe, H. Kimura, J. Okabe, A. Kato, H. Shimizu, T. Ueda, S. Shimada, and Y. Ogura Effect of Benzalkonium Chloride on Transscleral Drug Delivery Invest. Ophthalmol. Vis. Sci., February 1, 2005; 46(2): 703 - 708. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Aihara, J. D. Lindsey, and R. N. Weinreb Ocular Hypertension in Mice with a Targeted Type I Collagen Mutation Invest. Ophthalmol. Vis. Sci., April 1, 2003; 44(4): 1581 - 1585. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. W. Kim, J. D. Lindsey, M. Aihara, T. L. Anthony, and R. N. Weinreb Intraocular Distribution of 70-kDa Dextran after Subconjunctival Injection in Mice Invest. Ophthalmol. Vis. Sci., June 1, 2002; 43(6): 1809 - 1816. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |